Evidence map›Paper›PMID 40461861›Full record

ArticleBreast cancer research and treatment2025

A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer.

Kimberley T Lee, Bihe Hu, Dinorah Martinez Tyson, Carley Geiss, Susan T Vadaparampil, Heather S L Jim, Clement K Gwede, Hatem H Soliman, N Lynn Henry, Dawn L Hershman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kimberley T LeeDepartment of Breast Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Kimberley.lee@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-3346-0885
Bihe HuDepartment of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Dinorah Martinez TysonDepartment of Community and Family Health, University of South Florida, Tampa, FL, USA.
Carley GeissParticipant Research, Interventions and Measurement (PRISM) Core, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Susan T VadaparampilDepartment of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Heather S L JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Clement K GwedeDepartment of Health Outcomes and Behavior, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Hatem H SolimanDepartment of Breast Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
N Lynn HenryDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Dawn L HershmanDepartment of Breast Oncology, Herbert Irving Comprehensive Cancer Center at Columbia University, New York, NY, USA.

Funding

Developing a digital symptom monitoring intervention to improve adherence to endocrine therapy among breast cancer survivorsK08CA279076 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Kimberley T Lee · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA279076NIH HHS K08CA279076-01
6 · The paper itself

Abstract

purposeThe use of ovarian function suppression (OFS) for the treatment of breast cancer in pre-menopausal women is low and little is known about medical oncologist' attitudes toward current guidelines pertaining to the use of OFS. This purpose of this study was to explore breast medical oncologists' perceptions and use of gonadotropin-releasing hormone agonists as OFS for treatment of early-stage breast cancer.

methodsA quantitative survey exploring experiences with OFS was distributed to medical oncologists across the USA using mailing lists available through the American Medical Association. Survey responses were characterized using descriptive statistics.

resultsOncologists in this study reported high likelihood of recommending OFS for pre-menopausal women at high risk for recurrence of hormone receptor-positive early-stage breast cancer. In addition to tumor size, nodal involvement, and 21-gene recurrence scores, administration of chemotherapy was a strong surrogate for risk of recurrence. Concerns about treatment toxicity and patient hesitancy were the top barriers to OFS utilization. Oncologists also reported low confidence in their ability to determine menopausal status in the setting of amenorrhea post-chemotherapy (9% reported feeling very confident with this task) and to monitor ovarian function while on OFS.

conclusionOncologists reported strong agreement with established guidelines for the use of OFS in the treatment of early-stage hormone receptor-positive breast cancer. However, our findings indicate a need for guidance regarding the determination of menopausal status in the setting of amenorrhea and monitoring of ovarian function.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsGonadotropin-Releasing HormoneOncologistsPractice Patterns, Physicians'AdultAttitude of Health PersonnelFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPremenopauseSurveys and QuestionnairesAntineoplastic Agents, HormonalGonadotropin-Releasing HormoneBreast cancerGonadotropin-releasing hormone agonistOvarian function suppressionPre-menopausal

Identifiers

PMID40461861
PMCPMC12209034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.